Navigation Links
SureGene and PGXL Laboratories launch the SureGene Test for Antipsychotic and Antidepressant Response (STA2R)
Date:8/29/2012

LOUISVILLE, Ky., Aug. 29, 2012 /PRNewswire/ -- SureGene announced today that it has partnered with PGXL Laboratories, a CLIA-certified lab in Louisville, KY., to launch the SureGene Test for Antipsychotic and Antidepressant Response (STA2R), a breakthrough pharmacogenetic test containing genetic markers for effectiveness of antipsychotic drug treatment.  STA2R provides clinicians with valuable new information to facilitate personalized antipsychotic and antidepressant drug selection.

Millions of people each year are treated with antipsychotic drugs, and tens of millions are treated with antidepressants.  Very often, patients must try several drugs before finding the right one for them.  With the STA2R report, for the first time clinicians have useful medical information to augment their experience for selecting a drug treatment for each patient.

STA2R combines the propriety SULT4A1-1 genetic signature with four other gene tests. Clinical studies in Caucasian schizophrenic patients have indicated that SULT4A1-1 positive patients treated with olanzapine have greater reduction in psychotic symptoms and a significantly lower risk of being hospitalized.  Additionally STA2R helps identify those patients for whom risperidone, the current standard treatment, is contraindicated and patients that may not respond as well to certain antidepressants.

"STA2R represents a revolutionary change to the treatment of schizophrenia and bipolar disorder.  For the first time, physicians will have a test that can help them prioritize the treatment choices for their patients," say Dr. Bill W. Massey, President of SureGene.

STA2R has an easy collection process requiring only a simple cheek swab in the healthcare professional's office.  The swabs are then placed in the pre-paid shipping container, which is then delivered to PGXL Laboratories, a CLIA-certified lab in Louisville, KY.  Within a few days, the clinician receives a secure report.

SureGene discovered and patented the SULT4A1 genetic signature.  PGXL Laboratories independently developed the STA2R test and will exclusively perform the test in its laboratory.  SureGene is working with healthcare providers to promote the test.

About STA2R report:  The SureGene Test for Antipsychotic and Antidepressant Response (STA2R) is a panel of genetic tests that gives prescribers additional information upon which to base medication selection. The test provides information regarding the potential response of individual patients to antipsychotic and antidepressant treatment based upon the information known about their genetic makeup. This information covers three areas: clinical response, adverse event liability, and drug metabolism. Currently, the test provides detailed information for the most widely used atypical antipsychotics and antidepressants. While the test report describes the patient's most likely response to the listed drugs, every patient is unique and not all patients will respond in a typical fashion.

About SureGene:  SureGene, LLC, provides personalized solutions for the treatment of serious mental illnesses. SureGene discovers and develops personalized medicine tests that deliver exceptional clinical utility to address the high level of unmet medical need for the treatment of schizophrenia and bipolar disorder.

About PGXL Laboratories:  A privately-owned business located in Louisville, Kentucky, PGXL Laboratories was the first lab in the country CLIA-certified specifically to conduct pharmacogenetic tests. It offers pharmacogenetic testing, interpretive services, and assay design and validation. Along with its clinical practice, PGXL performs contract research for developers of pharmaceuticals and medical equipment.

For more information about STA2R please visit www.suregenetest.com.


'/>"/>
SOURCE SureGene, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Millennium Laboratories Announces Landmark Pharmacogenetics Clinical Outcomes Study
2. Use Notebook Studies to Ensure Successful Reusable Device Cleaning Validations, Recommends Microtest Laboratories
3. BD and PEPFAR Launch Labs for Life to Strengthen Laboratories in Regions Heavily Burdened by Disease
4. Carl Icahn Issues Open Letter to Shareholders of Forest Laboratories
5. Medica Announces Global Release of the EasyCell Assistant Analyzer for Hematology Laboratories
6. RoundTable Healthcare Partners Portfolio Company, Renaissance Acquisition Holdings, LLC Acquires DPT Laboratories
7. Carl Icahn Issues Letter To Howard Solomon Of Forest Laboratories
8. Millennium Laboratories Wins Lawsuit: Ameritox Advertisements Regarding Rx Guardian and Rx Guardian CD Contain Literally False Statements
9. Court Preliminarily Deems Millennium Laboratories Press Release Misleading
10. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
11. PeaceHealth Laboratories New Patent Addresses a Leading Cause of Death: Prescription Drug Abuse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Medical, Inc. (Nasdaq: AEMD ), the pioneer ... diseases, today announced results for the third quarter ... --> --> "Beyond ... quarterly call, we strategically advanced pre-clinical and clinical ... the Aethlon Hemopurifier® as a leading broad-spectrum countermeasure ...
(Date:2/4/2016)... N.Y. , Feb. 4, 2016  AMRI (NASDAQ:  AMRI) ... President of Pfizer Inc. and President of Pfizer Global Supply, ... as of February 4, 2016. In addition, the Company announced ... of the audit committee since 2010, has retired from the ... and attention to his other business ventures.  ...
(Date:2/4/2016)... PUNE, India , February 4, 2016 ... to the new Market Research Report "North American Automated ... and Fully-Automated External Defibrillators), by End-User (Public Facilities, Hospitals, ... North American automated external defibrillators (AED) report defines and ... of the revenue. This market is estimated to grow ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... February 06, 2016 , ... ... MEDIA ADVISORY: 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO ... in the world with an estimated 5000 perioperative nurses in attendance to ...
(Date:2/5/2016)... ... February 05, 2016 , ... Steven Tonkinson, 36, of ... completed every year since it started in 2003. This year, he ran all 26.2 ... fellow runners and NBA team the Miami Heat. , This Sunday, while many are ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... ... February 05, 2016 , ... After years as an active staff surgeon ... and cosmetic surgeon Dr. Wayne Carman transitioned to chief of the Division of Plastic ... first three-year term as chief and began a second three-year term in January of ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... gym use and find themselves having to wait longer to access the treadmills. It’s ... their New Year’s resolutions to lose weight and get in shape by joining gyms, ...
Breaking Medicine News(10 mins):